Deficiency or blockade of angiotensin II type 2 receptor delays tumorigenesis by inhibiting malignant cell proliferation and angiogenesis by N. Clere et al.
Deficiency or blockade of angiotensin II type 2 receptor
delays tumorigenesis by inhibiting malignant cell
proliferation and angiogenesis
Submitted by Emmanuel Lemoine on Thu, 02/27/2014 - 10:34
Titre Deficiency or blockade of angiotensin II type 2 receptor delays tumorigenesis byinhibiting malignant cell proliferation and angiogenesis
Type de
publication Article de revue
Auteur
Clere, Nicolas [1], Corre, Isabelle [2], Faure, Sébastien [3], Guihot, Anne-Laure [4],
Vessieres, Emilie [5], Chalopin, Matthieu [6], Morel, Alain [7], Coqueret, Olivier [8],
Hein, Lutz [9], Delneste, Yves [10], Paris, François [11], Henrion, Daniel [12]
Editeur Wiley








revue International Journal of Cancer
ISSN 1097-0215
Mots-clés
Angiotensin II Type 2 Receptor Blockers [13], Animals [14], Carcinoma, Lewis Lung
[15], Cell Growth Processes [16], Cell Transformation, Neoplastic [17], Female [18],
Fibrosarcoma [19], Gene Deletion [20], Imidazoles [21], Methylcholanthrene [22],
Mice [23], Mice, Inbred C57BL [24], Mice, Knockout [25], Neovascularization,
Pathologic [26], Pyridines [27], Receptor, Angiotensin, Type 2 [28], Reverse
Transcriptase Polymerase Chain Reaction [29], SOPAM [30], UNPUBLISHED [31]
Résumé en
anglais
Despite significant expression level in cancer cells, the role of the angiotensin II Type
2 receptor (AT2R) in cancer progression remains poorly understood. We aimed to
investigate the involvement of AT2R in tumorigenesis, hypothesizing a role in tumor
cell proliferation and/or tumor angiogenesis. Two animal tumor models were used:
fibrosarcoma induced by 3-methylcholanthrene (3-MCA) in FVB/N mice invalidated
for AT2R (AT2R-KO) and carcinoma LL/2 cells injected in C57BL/6N mice treated
with AT2R antagonist PD123,319. Tumor growth was monitored, microvascular
density (MVD) evaluated by CD31 staining. Proliferation index of LL/2 and 3-MCA
tumor cells was evaluated by expression of Ki-67. Angiogenesis was assessed by
aorta ring assay and angiogenic mediators' expression by real-time RT-PCR. Tumor
induction by 3-MCA was significantly delayed in AT2R-KO compared to wild-type
mice (56 days vs. 28 days). Tumorigenesis following LL/2 cell injection in mice was
also significantly reduced by early administration of the antagonist PD123,319. In
vitro, inactivation or invalidation of AT2R inhibited proliferation of LL/2 and 3-MCA
tumor cells, respectively. Tumor MVD was reduced in mice treated early with
PD123,319. Ex vivo experiments revealed a significant decrease in angiogenesis after
PD123,319 treatment or in AT2R-KO mice. Finally, we identified vascular endothelial
growth factor (VEGF) as a soluble proangiogenic factor produced by LL/2 cells and
we showed that in LL/2 and 3-MCA tumor cells, inhibition or deficiency of AT2R was
associated with impaired production of proangiogenic factors included VEGF. This
study uncovered novel mechanisms by which AT2R would promote tumor
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